PMID- 21856725
OWN - NLM
STAT- MEDLINE
DCOM- 20111215
LR  - 20131121
IS  - 1462-0332 (Electronic)
IS  - 1462-0324 (Linking)
VI  - 50
IP  - 11
DP  - 2011 Nov
TI  - Age at treatment predicts reason for discontinuation of TNF antagonists: data 
      from the BIOBADASER 2.0 registry.
PG  - 1999-2004
LID - 10.1093/rheumatology/ker281 [doi]
AB  - OBJECTIVES: To assess the retention rate of TNF antagonists in elderly patients 
      suffering from chronic arthropathies and to identify predictive variables of 
      discontinuation by inefficacy or by adverse events (AEs). METHODS: All patients 
      treated with TNF antagonists in BIOBADASER 2.0, with a diagnosis of either RA or 
      spondyloarthritis (SpA: AS and PsA) were included and classified as <65 (younger) 
      or >/=65 years of age (older) at start of the treatment. Cumulative incidence 
      function for discontinuation (inefficacy or AE) was estimated as being the 
      alternative reason for a competing risk. Competing-risks regression models were 
      used to measure the association between study groups, covariates and reason for 
      discontinuation. RESULTS: A total of 4851 patients were studied; 2957 RA (2291 in 
      the younger group and 666 in the older group) and 1894 SpA (1795 in the younger 
      group and 99 in the older group). Retention curves were statistically differently 
      stratified by age groups, with the SpA younger group having the largest retention 
      rate. Competing-risks regression models showed that in the older group, AEs were 
      the most common reason for discontinuation regardless of the diagnosis of the 
      patient and TNF antagonist molecule, whereas in the younger group, the most 
      common cause of discontinuation was inefficacy. CONCLUSION: In conclusion, 
      factors predicting discontinuation of TNF antagonists due to AEs are older age 
      and diagnosis of RA. On the other hand, younger age predicts discontinuation due 
      to lack of efficacy.
FAU - Busquets, Noemi
AU  - Busquets N
AD  - Rheumatology Department, Hospital de Granollers, Granolllers, Barcelona.
FAU - Tomero, Eva
AU  - Tomero E
FAU - Descalzo, Miguel Angel
AU  - Descalzo MA
FAU - Ponce, Andres
AU  - Ponce A
FAU - Ortiz-Santamaria, Vera
AU  - Ortiz-Santamaria V
FAU - Suris, Xavier
AU  - Suris X
FAU - Carmona, Loreto
AU  - Carmona L
FAU - Gomez-Reino, Juan J
AU  - Gomez-Reino JJ
CN  - BIOBADASER 2.0 Study Group
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110819
PL  - England
TA  - Rheumatology (Oxford)
JT  - Rheumatology (Oxford, England)
JID - 100883501
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Cohort Studies
MH  - Drug Resistance
MH  - Drug-Related Side Effects and Adverse Reactions/etiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Registries
MH  - Spondylitis, Ankylosing/*drug therapy
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
MH  - *Withholding Treatment
FIR - Sellas, Agusti
IR  - Sellas A
FIR - Rodriguez, Basilio
IR  - Rodriguez B
FIR - Barcelo, Mireia
IR  - Barcelo M
FIR - Farietta, Sandra
IR  - Farietta S
FIR - Montoro, Maria
IR  - Montoro M
FIR - Gonzalez, Ainhoa
IR  - Gonzalez A
FIR - Herraaez, Elena
IR  - Herraaez E
FIR - Ruiz-Montesino, Maria Dolores
IR  - Ruiz-Montesino MD
FIR - Vargas, Carmen
IR  - Vargas C
FIR - Perez-Pampin, Eva
IR  - Perez-Pampin E
FIR - Ortiz, Ana Maria
IR  - Ortiz AM
FIR - Tomero, Eva
IR  - Tomero E
FIR - Anton, Fred
IR  - Anton F
FIR - Zea, Antonio
IR  - Zea A
FIR - Ruiz, Francisco Javier Manero
IR  - Ruiz FJ
FIR - Beltran, Chesus
IR  - Beltran C
FIR - Ubeda, Eugenio Gimenez
IR  - Ubeda EG
FIR - Zorzo, Fernando Jimenez
IR  - Zorzo FJ
FIR - Marzo, Jesus
IR  - Marzo J
FIR - Medrano, Marta
IR  - Medrano M
FIR - Pecondon, Angela
IR  - Pecondon A
FIR - Hernandez, Maria Victoria
IR  - Hernandez MV
FIR - Sanmartii, Raimon
IR  - Sanmartii R
FIR - Canete, Juan D
IR  - Canete JD
FIR - Lozano, Carlos Rodriguez
IR  - Lozano CR
FIR - Naranjo, Antonio
IR  - Naranjo A
FIR - Ojeda, Soledad
IR  - Ojeda S
FIR - Hernandez, Felix Francisco
IR  - Hernandez FF
FIR - Erausquin, Celia
IR  - Erausquin C
FIR - Ruua, Inigo
IR  - Ruua I
FIR - Quevedo, Juan Carlos
IR  - Quevedo JC
FIR - Urena, Inmaculada
IR  - Urena I
FIR - Irigoyen, Maria Victoria
IR  - Irigoyen MV
FIR - Cano, Laura
IR  - Cano L
FIR - Pardo, Rosa Rosello
IR  - Pardo RR
FIR - Mateo, Isabel
IR  - Mateo I
FIR - Garcia, Javier
IR  - Garcia J
FIR - Enriquez, Eugenia
IR  - Enriquez E
FIR - Campos, Cristina
IR  - Campos C
FIR - Borras, Juan Jose Garcia
IR  - Borras JJ
FIR - Negueroles, Rosa
IR  - Negueroles R
FIR - Munoz, Luisa
IR  - Munoz L
FIR - Valero, J L
IR  - Valero JL
FIR - Ibanez, D
IR  - Ibanez D
EDAT- 2011/08/23 06:00
MHDA- 2011/12/16 06:00
CRDT- 2011/08/23 06:00
PHST- 2011/08/23 06:00 [entrez]
PHST- 2011/08/23 06:00 [pubmed]
PHST- 2011/12/16 06:00 [medline]
AID - ker281 [pii]
AID - 10.1093/rheumatology/ker281 [doi]
PST - ppublish
SO  - Rheumatology (Oxford). 2011 Nov;50(11):1999-2004. doi: 
      10.1093/rheumatology/ker281. Epub 2011 Aug 19.